FDA Approves Alnylam's Onpattro for Polyneuropathy of hATTR Amyloidosis

11:50 EDT 10 Aug 2018 | Genetic Engineering News

The FDA today granted Alnylam Pharmaceuticals approval for a first-in-class small interfering ribonucleic acid (siRNA) treatment—the first therapy indicated for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Onpattro™ (patisiran) is an infusion treatment whose approval comes 20 years after the discovery of RNA interference. Onpattro is designed to interfere with RNA production of an abnormal form of the protein transthyretin (TTR). By preventing the production of TTR, the drug is intended to help reduce the accumulation of amyloid deposits in peripheral nerves, improving symptoms and helping patients better manage their polyneuropathy. “Alnylam was founded on the vision of harnessing the potential of RNAi therapeutics to treat human disease, and this approval heralds the arrival of an entirely new class of medicines,” Alnlyam CEO John Maraganore, Ph.D., said in a statement. We believe today draws us ever-closer to achieving our Alnylam 2020 goals of becoming a ...

Original Article: FDA Approves Alnylam's Onpattro for Polyneuropathy of hATTR Amyloidosis


More From BioPortfolio on "FDA Approves Alnylam's Onpattro for Polyneuropathy of hATTR Amyloidosis"

Quick Search


Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...